Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification

Carla Montironi(Hospital Clínic de Barcelona), Florian Castet(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Philipp K. Haber(Icahn School of Medicine at Mount Sinai), Roser Pinyol(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Miguel Torres‐Martín(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Laura Torrens(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Agavni Mesropian(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Huan Wang(Sema4 (United States)), Marc Puigvehí(Parc de Salut), Miho Maeda(Icahn School of Medicine at Mount Sinai), Wei Qiang Leow(Singapore General Hospital), Elizabeth Harrod(Royal Surrey County Hospital), Patricia Taik(Sema4 (United States)), Jigjidsuren Chinburen(National Center for Communicable Diseases), Erdenebileg Taivanbaatar(National Center for Communicable Diseases), Chinbold Enkhbold(National Center for Communicable Diseases), M. Solé Arqués(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Michael Donovan(Icahn School of Medicine at Mount Sinai), Swan N. Thung(Icahn School of Medicine at Mount Sinai), Jaclyn Neely(Bristol-Myers Squibb (United States)), Vincenzo Mazzaferro, Jeffrey Anderson(Bristol-Myers Squibb (United States)), Sasan Roayaie(White Plains Hospital), Myron Schwartz(Icahn School of Medicine at Mount Sinai), Augusto Villanueva(Icahn School of Medicine at Mount Sinai), Scott L. Friedman(Icahn School of Medicine at Mount Sinai), Andrew Uzilov(Sema4 (United States)), Daniela Sia(Icahn School of Medicine at Mount Sinai), Josep M. Llovet(Institució Catalana de Recerca i Estudis Avançats)
Gut
February 23, 2022
Cited by 235Open Access
Full Text

Abstract

Objective We previously reported a characterisation of the hepatocellular carcinoma (HCC) immune contexture and described an immune-specific class. We now aim to further delineate the immunogenomic classification of HCC to incorporate features that explain responses/resistance to immunotherapy. Design We performed RNA and whole-exome sequencing, T-cell receptor (TCR)-sequencing, multiplex immunofluorescence and immunohistochemistry in a novel cohort of 240 HCC patients and validated our results in other cohorts comprising 660 patients. Results Our integrative analysis led to define: (1) the inflamed class of HCC (37%), which includes the previously reported immune subclass (22%) and a new immune-like subclass (15%) with high interferon signalling, cytolytic activity, expression of immune-effector cytokines and a more diverse T-cell repertoire. A 20-gene signature was able to capture ~90% of these tumours and is associated with response to immunotherapy. Proteins identified in liquid biopsies recapitulated the inflamed class with an area under the ROC curve (AUC) of 0.91; (2) The intermediate class, enriched in TP53 mutations (49% vs 29%, p=0.035), and chromosomal losses involving immune-related genes and; (3) the excluded class, enriched in CTNNB1 mutations (93% vs 27%, p<0.001) and PTK2 overexpression due to gene amplification and promoter hypomethylation. CTNNB1 mutations outside the excluded class led to weak activation of the Wnt-βcatenin pathway or occurred in HCCs dominated by high interferon signalling and type I antigen presenting genes. Conclusion We have characterised the immunogenomic contexture of HCC and defined inflamed and non-inflamed tumours. Two distinct CTNNB1 patterns associated with a differential role in immune evasion are described. These features may help predict immune response in HCC.


Related Papers

No related papers found

Powered by citation graph analysis